Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Bupropion Sustained Release Clear all
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

NCT03047005
View directory record Official record
Conditions
Binge-Eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Maintenance Treatment for Abstinent Smokers

NCT00063323
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 75 Years
Enrollment
589 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease

NCT02162862
View directory record Official record
Conditions
Sleep Disturbance, Fatigue, Inflammatory Bowel Disease
Interventions
Behavioral Counseling, bupropion-SR
Behavioral · Drug
Lead sponsor
Eva Szigethy
Other
Eligibility
15 Years to 30 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

NCT00865111
View directory record Official record
Conditions
Healthy
Interventions
Bupropion 150 mg Extended-Released Tablet, single dose, Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2010 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

A Study Using Functional Magnetic Resonance Imaging (fMRI) to Assess the Effects of Naltrexone SR/ Bupropion SR Therapy in Overweight or Obese Subjects

NCT00711477
View directory record Official record
Conditions
Obesity
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, fMRI scan
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Upton, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

NCT00563563
View directory record Official record
Conditions
Nicotine Dependence, Overweight, Obesity
Interventions
NB32, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

NCT00532779
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns

NCT02078180
View directory record Official record
Conditions
Depression
Interventions
generic bupropion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional

Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease

NCT00181818
View directory record Official record
Conditions
Smoking, Myocardial Infarction, Unstable Angina, Cardiovascular Disease
Interventions
bupropion SR (sustained-release)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery

NCT02173886
View directory record Official record
Conditions
Roux en Y Gastric Bypass
Interventions
Bupropion SR and XL
Drug
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

NCT00567255
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 4 Interventional Results available

Bupropion for Depression in ESRD Patients on Hemodialysis

NCT02238977
View directory record Official record
Conditions
Major Depression, End Stage Renal Disease
Interventions
Fluoxetine, Bupropion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bupropion on Seizure Threshold in Depressed Patients

NCT03126682
View directory record Official record
Conditions
MDD
Interventions
Wellbutrin SR 300Mg Extended-Release Tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

AXS-05 Phase II Trial on Smoking Behavior

NCT03471767
View directory record Official record
Conditions
Smoking Cessation, Smoking, Cigarette, Nicotine Dependence
Interventions
AXS-05, Bupropion SR
Drug
Lead sponsor
James Davis
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

NCT03045341
View directory record Official record
Conditions
Binge-eating Disorder, Obesity
Interventions
NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Sep 9, 2026, 11:15 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

NCT00419731
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion, Bupropion + Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

NCT00307203
View directory record Official record
Conditions
Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions
bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

NCT01714323
View directory record Official record
Conditions
Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder
Interventions
Sustained Care, Standard Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Salem, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

NCT00625859
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Bupropion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Nicotine Patch Pretreatment for Smoking Cessation in PTSD

NCT00625131
View directory record Official record
Conditions
Stress Disorders, Posttraumatic, Tobacco Use Disorder
Interventions
Nicotine, Cognitive Behavioral Therapy for Smoking Cessation, Bupropion Sustained Release (SR), Placebo patch
Drug · Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treating Smokeless Tobacco Use in Rural Veterans

NCT02994082
View directory record Official record
Conditions
Smokeless Tobacco, Nicotine Dependence
Interventions
Tailored behavioral intervention, Behavioral activation for elevated depressive symptoms, Post-cessation weight gain management, Alcohol use risk reduction, Nicotine replacement therapy - transdermal nicotine patch, Nicotine replacement therapy - nicotine lozenge, Nicotine replacement therapy - nicotine gum, Bupropion sustained release, Varenicline, Combination nicotine replacement therapy, Combination nicotine replacement therapy + bupropion, Tobacco quit line, Educational materials
Behavioral · Drug
Lead sponsor
Mark Vander Weg
Federal
Eligibility
18 Years to 99 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

NCT00474630
View directory record Official record
Conditions
Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions
Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
53
States / cities
Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

NCT00456521
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional

Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity

NCT00709371
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide SR placebo/ bupropion SR placebo, Zonisamide SR placebo/ bupropion SR 360 mg/day, Zonisamide SR 120 mg/day/ bupropion SR placebo, Zonisamide SR 360 mg/day/ bupropion SR placebo, Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day, Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fairhope, Alabama • La Jolla, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Sep 9, 2026, 11:15 AM EDT